Core Viewpoint - Jilin Changlong Pharmaceutical (08049) reported a revenue of 439 million RMB for the six months ending June 30, 2025, representing an 11.6% year-on-year increase, while the profit attributable to shareholders decreased by 1.2% to 103 million RMB [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 439 million RMB, up 11.6% compared to the same period last year [1] - Profit attributable to shareholders was 103 million RMB, reflecting a decline of 1.2% year-on-year [1] - Basic earnings per share were 18.38 cents [1] Margins and Costs - The gross margin for the period was approximately 82.4%, which is an increase compared to the period ending June 30, 2024 [1] - The board attributes the improved gross margin to a reduction in production and material costs [1]
吉林长龙药业发布中期业绩，股东应占溢利1.03亿元，同比下降1.2%